Bicycle therapeutics announces pricing of upsized public offering of $175 million of american depositary shares

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the pricing of an underwritten public offering of 3,240,741 american depositary shares (“adss”), each representing one ordinary share, at a price to the public of $54.00 per ads, for gross proceeds of $175.0 million. in addition, bicycle has granted
BCYC Ratings Summary
BCYC Quant Ranking